Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $1.03M rose 156.8% year over year, ahead of the +66.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at +77.3% a year.
Context
- Depreciation & amortization amounted to 0.4% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +156.8% holds above the trailing-twelve-month pace of +66.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.82M USD
- Year-over-year change
- +48.2%
- 4-year CAGR
- +55.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.82M | +48.2% |
| FY2024 | 2024-12-31 | 1.23M | +39.7% |
| FY2023 | 2023-12-31 | 877K | +169.0% |
| FY2022 | 2022-12-31 | 326K | +4.5% |
| FY2021 | 2021-12-31 | 312K | — |
Depreciation & Amortization vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 depreciation & amortization of $2.91M is the 2nd largest of the 6 companies compared; the peer median is $670K.
- Its year-over-year change of +66.6% is the highest of 4, against a peer median of -41.1%.
- Depreciation & amortization amounts to 0.4% of revenue for TARS, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.35M | +25.1% | +75.1% | 7.6% | |
| LTM Sep 2026 | $2.91M | +66.6% | +77.3% | 0.4% | |
| LTM Jun 2026 | $2.25M | -58.5% | +71.0% | 0.5% | |
| LTM Mar 2026 | $670K | -41.1% | -15.8% | 1.8% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $42.29K | — | — | — |
| LTM Jun 2024 | $0 | — | -42.1% | 0.0% | |
| Peer median (excluding TARS) | $670K | -41.1% | +27.6% | 1.1% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.46M | 13.46M | 19.83M | 27.82M | 41.72M |
| Change in Working Capital | 1.37M | (951K) | 306K | 3.84M | 14.64M |
| Accounts Receivables | (73K) | (3.49M) | (14.13M) | (30.14M) | (39.05M) |
| Inventory | 0 | 3.49M | (3.11M) | (2.05M) | (1.75M) |
| Accounts Payables | 3.88M | 821K | 13.24M | 40.34M | 6.91M |
| Other Working Capital | (2.44M) | (1.77M) | 4.3M | (4.31M) | 48.53M |
| Other Non-Cash Items | 7.44M | 226K | (2.61M) | (360K) | (4.21M) |
| Operating Cash Flow | 3.75M | (49.03M) | (117.49M) | (83.03M) | (12.45M) |
| Capital Expenditures | (586K) | (506K) | (5.5M) | (1.57M) | (9.86M) |
| Acquisitions (Net) | 0 | 144.12M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (149.44M) | (28.66M) | (265.63M) | (394.06M) |
| Sales of Investments | 0 | 5.32M | 174.77M | 73M | 361.8M |
| Other Investing Activities | 0 | (144.12M) | (4M) | (5M) | 0 |
| Investing Cash Flow | (586K) | (144.63M) | 140.6M | (199.2M) | (42.12M) |
| Debt Repayment | 0 | 19.13M | 10M | 39.6M | 0 |
| Common Stock Issued | 21K | 74.86M | 120.18M | 115.06M | 143.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 21K | 93.99M | 130.18M | 154.66M | 143.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.18M | (99.67M) | 153.29M | (127.57M) | 88.82M |
| Free Cash Flow | 3.16M | (49.54M) | (123M) | (84.59M) | (22.31M) |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.